ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

June 4, 2020

The Centers for Medicare & Medicaid Services Innovation Center (CMMI) announced new flexibilities and adjustments to its current and future alternative payment models in response to the COVID-19 Public Health Emergency (PHE).

June 3, 2020

I hope this message finds you safe and well. Months ago when I defined a theme for my year as ASCO President, “Equity:  Every Patient. Every Day. Everywhere,” I never imagined we would experience a healthcare pandemic that would disproportionally impact people of color. Nor could I know this would be the moment when yet another brutal crime against an African American would so capture the nation’s attention and bring long-simmering pain to the surface. 

June 2, 2020

As previously reported, $50 billion from the Provider Relief Fund has been allocated by the U.S. Department of Health and Human Services (HHS) for general distribution to Medicare facilities and providers impacted by COVID-19. To be eligible for the general distribution, a provider must have billed Medicare in 2019.

June 1, 2020

A MedWatch Safety Alert was added to the FDA Medical Device Safety webpage.

TOPIC: STERRAD Sterilization Systems: Letter to Health Care Providers - Use the Correct Cycle and Compatible N95 Respirators When Decontaminating Respirators

AUDIENCE: Health Professional, Risk Manager

June 1, 2020

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:

On May 29, 2020, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.

June 1, 2020

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:

On May 29, 2020, the Food and Drug Administration approved atezolizumab in combination with bevacizumab (TECENTRIQ® and AVASTIN®, Genentech Inc.) for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

May 29, 2020

On May 29, ASCO's CancerLinQ® announced it had launched a new platform for CancerLinQ Discovery®, its de-identified real-world cancer data product for researchers across the cancer community. 

May 26, 2020

In an open letter, the Regulatory Relief Coalition (RRC) called on all health plans in the United States to suspend prior authorization requirements for both COVID-19 and non-COVID-19-related services during the novel coronavirus pandemic. The Association for Clinical Oncology (ASCO) is a member of RRC, which is a group of national physician specialty organizations advocating for regulatory burden reduction in Medicare.  

May 26, 2020

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: 

On May 22, 2020, the Food and Drug Administration approved brigatinib (ALUNBRIG®, ARIAD Pharmaceuticals Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Today, the FDA also approved the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular, Inc.) as a companion diagnostic for brigatinib.

May 20, 2020

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:

On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA®, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.

May 19, 2020

ASCO released the ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemicwhich provides detailed guidance to oncology practices on the immediate and short-term steps that could be taken to help protect the safety of patients and healthcare staff before resuming more routine care operations during the COVID-19 public health crisis.

May 18, 2020

A new infographic in the May 2020 print and online issues of JCO Oncology Practice (JCO OP) outlines paths to implementing the American Society of Clinical Oncology’s (ASCO) Patient-Centered Oncology Payment (PCOP) model—an alternative payment model designed to support transformation in cancer care delivery and reimbursement while ensuring that patients with cancer have access to high-quality care.

May 15, 2020

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:

On May 15, 2020, the Food and Drug Administration approved ripretinib (QINLOCK, Deciphera Pharmaceuticals, LLC.), for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Pages